|
Index | - | P/E | - | EPS (ttm) | -1.91 | Insider Own | 4.20% | Shs Outstand | 13.37M | Perf Week | -18.91% |
Market Cap | 143.70M | Forward P/E | - | EPS next Y | -0.53 | Insider Trans | -41.31% | Shs Float | 6.17M | Perf Month | -27.13% |
Income | -19.00M | PEG | - | EPS next Q | -0.10 | Inst Own | 12.20% | Short Float | 0.88% | Perf Quarter | 26.02% |
Sales | - | P/S | - | EPS this Y | -263.00% | Inst Trans | - | Short Ratio | 0.64 | Perf Half Y | 81.47% |
Book/sh | 1.72 | P/B | 5.01 | EPS next Y | -26.20% | ROA | -138.90% | Target Price | - | Perf Year | -64.82% |
Cash/sh | 0.92 | P/C | 9.33 | EPS next 5Y | - | ROE | -180.10% | 52W Range | 3.40 - 14.24 | Perf YTD | 30.71% |
Dividend | - | P/FCF | - | EPS past 5Y | -5.70% | ROI | - | 52W High | -39.96% | Beta | 0.16 |
Dividend % | - | Quick Ratio | 13.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 151.47% | ATR | 0.71 |
Employees | 14 | Current Ratio | 13.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 28.86 | Volatility | 6.37% 6.71% |
Optionable | No | Debt/Eq | 0.00 | EPS Q/Q | -361.70% | Profit Margin | - | Rel Volume | 0.16 | Prev Close | 8.62 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | Mar 25 AMC | Payout | - | Avg Volume | 84.85K | Price | 8.55 |
Recom | 2.00 | SMA20 | -21.39% | SMA50 | -19.50% | SMA200 | 6.22% | Volume | 6,605 | Change | -0.81% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of gastroparesis; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It has a license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was incorporated in 2011 and is based in Hanover, Maryland. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
open in yahoo | open in reuters | open in marketwatch | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite